Diagnostic value of placental growth factor in patients with coronary heart disease
https://doi.org/10.17650/1818-8338-2012-3-4-28-32
Abstract
Objective: to study the diagnostic value of placental growth factor (PlGF) in patients with coronary heart disease (CHD).
Subjects and methods. 151 patients (75 men and 76 women; mean age 58.9 ± 12.3 years), including 66 patients with exercise-induced stable angina, 32 with unstable angina, 32 with myocardial infarction, and 21 with no clinical signs of CHD), were followed up. Blood PlGF levels were measured in all the examinees; C-reactive protein (CRP) concentrations were also determined using a high-sensitivity method in the patients with CHD.
Results. In the patients with acute coronary syndrome (ACS), the levels of PlGF were significantly higher than in those with exercise-induced stable angina and in healthy individuals (17.3 ± 11.4 versus 11.2 ± 7.3 and 8.8 ± 6.7 pg/ml; p < 0.001). Estimation of the diagnostic value of the determination of PlGF levels in the diagnosis of ACS in troponin-negative examinees revealed that the area under the ROC curve (AUC) was 0.76. The quality of a diagnostic model using CRP was inferior to that with PlGF (n = 45; AUC for PlGF = 0.79; that for CRP = 0.65).
Conclusion. The elevated level of PlGF may be considered as a diagnostic marker for ACS, including in the absence of the higher levels of cardiac troponins.
About the Authors
M. V. Tulikov
Clinical Hospital, Department for Presidential Affairs of the Russian Federation
Russian Federation
Russian Federation
O. P. Shevchenko
Faculty for Postgraduate Training of Physicians,
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
Department of Cardiology
Russian Federation
Department of Cardiology
A. O. Shevchenko
Faculty for Postgraduate Training of Physicians,
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
Department of Cardiology
Russian Federation
Department of Cardiology
Ye. V. Shin
Clinical Hospital, Department for Presidential Affairs of the Russian Federation
Russian Federation
Russian Federation
A. V. Gagayev
Clinical Hospital, Department for Presidential Affairs of the Russian Federation
Russian Federation
Russian Federation
V. V. Pavlov
Clinical Hospital, Department for Presidential Affairs of the Russian Federation
Russian Federation
Russian Federation
References
1. Ribatti D. The discovery of the placental growth factor and its role in angiogenesis: a historical review. Angiogenesis 2008;11(3):215–21.
2. Fam N.P., Verma S., Kutryk M., Stewart D.J. Clinician guide to angiogenesis. Circulation 2003;108(21):2613–8.
3. Henry T.D., Annex B.H., Azrin M.A. et al. Final results of the VIVA trial of rhVEGF for human therapeutic angiogenesis. Circulation 1999;100(supplI):1–476.
4. Luttun A., Tjwa M., Moons L. et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002;8(8):831–40.
5. Tjwa M., Luttun A., Autiero M., Carmeliet P. VEGF and PlGF: two pleiotropic growth factors with distinct roles in development and homeostasis. Cell Tissue Res 2003;314(1):5–14.
6. Heeschen C., Dimmeler S., Fichtlscherer S. et al. Prognostic value of placental growth factor in patients with acute chest pain. JAMA 2004;291(4):435–41.
7. Pipp F., Heil M., Issbrücker K. et al. VEGFR-1-selective VEGF homologue PlGF is arteriogenic: evidence for a monocyte-mediated mechanism. Circ Res 2003;92(4):378–85.
8. Selvaraj S.K., Giri R.K., Perelman N. et al. Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor. Blood 2003;102(4):1515–24.
9. Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med 1999;340(2):115–26.
10. Оганов Р.Г., Закирова Н.Э., Закирова А.Н. и др. Иммуновоспалительные реакции при остром коронарном синдроме. Рационал фармакотер кардиол 2007;3(5):15–9.
11. Felmeden D.C., Blann A.D., Lip G.Y. Angiogenesis: basic pathophysiology and implications for disease. Eur Heart J 2003;24(7):586–603.
12. Geng Y.J., Libby P. Progression of Atheroma: A Struggle between Death and Procreation. Arterioscler Thromb Vasc Biol 2002;22(9):1370–80.
13. Kolodgie F.D., Gold H.K., Burke A.P. et al. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med 2003;349(24):2316–25.
14. Barger A.C., Beeuwkes R. 3rd, Lainey L.L., Silverman K.J. Hypothesis: vasa vasorum and neovascularization of human coronary arteries. A possible role in the pathophysiology of atherosclerosis. N Engl J Med 1984;310(3):175–7.
15. Virmani R., Kolodgie F.D., Burke A.P. et al. Atherosclerotic plaque progression and vulnerability to rupture. Angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol
16. ;25(10):2054–61.
17. Apple F.S., Wu A.H., Mair J. et al. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem 2005;51(5):810–24.
Review
For citations:
Tulikov M.V., Shevchenko O.P., Shevchenko A.O., Shin Ye.V., Gagayev A.V., Pavlov V.V. Diagnostic value of placental growth factor in patients with coronary heart disease. The Clinician. 2012;6(3-4):28-32. (In Russ.) https://doi.org/10.17650/1818-8338-2012-3-4-28-32
Views:
782
Email this article 